NASDAQ: RNTX
Rein Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for RNTX

Based on 2 analysts offering 12 month price targets for Rein Therapeutics Inc

Min Forecast
$4.00+409.55%
Avg Forecast
$6.00+664.33%
Max Forecast
$8.00+919.11%

Should I buy or sell RNTX stock?

Based on 2 analysts offering ratings for Rein Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RNTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RNTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their RNTX stock forecasts and price targets.

RNTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-18
lockedlocked$00.00+00.00%2026-07-20

1 of 1

Forecast return on equity

Is RNTX forecast to generate an efficient return?

Company
N/A
Industry
19.18%
Market
168.79%

Forecast return on assets

Is RNTX forecast to generate an efficient return on assets?

Company
N/A
Industry
23.59%

RNTX earnings per share forecast

What is RNTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.47
Avg 2 year Forecast
-$0.47
Avg 3 year Forecast
-$0.61

RNTX revenue forecast

What is RNTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

RNTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RNTX$0.79$6.00+664.33%Strong Buy
NMAD$4.17N/AN/A
TENX$1.83$22.33+1,120.38%Buy
GANX$1.57$6.50+314.01%Strong Buy
SPRO$1.18$6.00+408.47%Buy

Rein Therapeutics Stock Forecast FAQ

Is Rein Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: RNTX) stock is to Strong Buy RNTX stock.

Out of 2 analysts, 1 (50%) are recommending RNTX as a Strong Buy, 1 (50%) are recommending RNTX as a Buy, 0 (0%) are recommending RNTX as a Hold, 0 (0%) are recommending RNTX as a Sell, and 0 (0%) are recommending RNTX as a Strong Sell.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.

What is RNTX's earnings growth forecast for 2026-2028?

(NASDAQ: RNTX) Rein Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.22%.

Rein Therapeutics's earnings in 2026 is -$49,761,000.On average, 4 Wall Street analysts forecast RNTX's earnings for 2026 to be -$40,476,491, with the lowest RNTX earnings forecast at -$39,734,595, and the highest RNTX earnings forecast at -$40,761,173. On average, 4 Wall Street analysts forecast RNTX's earnings for 2027 to be -$40,916,453, with the lowest RNTX earnings forecast at -$42,270,846, and the highest RNTX earnings forecast at -$38,949,565.

In 2028, RNTX is forecast to generate -$52,355,462 in earnings, with the lowest earnings forecast at -$56,642,933 and the highest earnings forecast at -$47,101,799.

What is RNTX's revenue growth forecast for 2026-2028?

(NASDAQ: RNTX) Rein Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.03%.

Rein Therapeutics's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast RNTX's revenue for 2026 to be $0, with the lowest RNTX revenue forecast at $0, and the highest RNTX revenue forecast at $0. On average, 4 Wall Street analysts forecast RNTX's revenue for 2027 to be $0, with the lowest RNTX revenue forecast at $0, and the highest RNTX revenue forecast at $0.

In 2028, RNTX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is RNTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RNTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.59%.

What is RNTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year RNTX price target, the average RNTX price target is $6.00, with the highest RNTX stock price forecast at $8.00 and the lowest RNTX stock price forecast at $4.00.

On average, Wall Street analysts predict that Rein Therapeutics's share price could reach $6.00 by Aug 18, 2027. The average Rein Therapeutics stock price prediction forecasts a potential upside of 664.33% from the current RNTX share price of $0.79.

What is RNTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RNTX) Rein Therapeutics's current Earnings Per Share (EPS) is -$1.72. On average, analysts forecast that RNTX's EPS will be -$0.47 for 2026, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.47. On average, analysts forecast that RNTX's EPS will be -$0.47 for 2027, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.45. In 2028, RNTX's EPS is forecast to hit -$0.61 (min: -$0.66, max: -$0.55).

What is RNTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RNTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.